A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig® in Routine Clinical Practice in the United States (US).

Trial Profile

A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig® in Routine Clinical Practice in the United States (US).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms OMNI
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 The primary analysis will be performed 12 mo after last patient enrolled and will estimate the incidence of VOEs by duration of ponatinib exposure as per trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 25 Jan 2016 Planned End Date changed from 1 Oct 2019 to 1 Jun 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top